Lauren C Peres1, Kara L Cushing-Haugen2, Michael Anglesio3, Kristine Wicklund2, Rex Bentley4, Andrew Berchuck5, Linda E Kelemen6, Tayyebeh M Nazeran7, C Blake Gilks7, Holly R Harris2, David G Huntsman7, Joellen M Schildkraut8, Mary Anne Rossing2, Martin Köbel9, Jennifer A Doherty10. 1. Department of Public Health Sciences, University of Virginia, 560 Ray C. Hunt Dr., P.O. Box 800765, Charlottesville, VA 22903, USA. Electronic address: lcp3t@virginia.edu. 2. Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1110 Fairview Avenue N, Seattle, WA 98109, USA. 3. Department of Obstetrics and Gynecology, University of British Columbia, 2660 Oak Street, Vancouver, British Columbia V6H 3Z6, Canada. 4. Department of Pathology, Duke University Medical Center, 2301 Erwin Rd., Durham, NC 27710, USA. 5. Department of Obstetrics and Gynecology, Duke University Medical Center, 25171 Morris Bldg., Durham, NC 27710, USA. 6. Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, 68 President St., MSC955, Charleston, SC 29425, USA. 7. Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada. 8. Department of Public Health Sciences, University of Virginia, 560 Ray C. Hunt Dr., P.O. Box 800765, Charlottesville, VA 22903, USA. 9. Department of Pathology and Laboratory Medicine, University of Calgary, Calgary Laboratory Services, 1403 29 St NW, Calgary, Alberta T2N 2T9, Canada. 10. Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
Abstract
OBJECTIVE: Major changes in the classification of ovarian carcinoma histotypes occurred over the last two decades, resulting in the current 2014 World Health Organization (WHO) diagnostic criteria that recognize five principal histotypes: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. We assessed the impact of these guidelines and use of immunohistochemical (IHC) markers on classification of ovarian carcinomas in existing population-based studies. METHODS: We evaluated histotype classification for 2361 ovarian carcinomas diagnosed between 1999 and 2009 from two case-control studies using three approaches: 1. pre-2014 WHO ("historic") histotype; 2. Standardized review of pathology slides using the 2014 WHO criteria alone; and 3. An integrated IHC assessment along with the 2014 WHO criteria. We used Kappa statistics to assess agreement between approaches, and Kaplan-Meier survival curves and Cox proportional hazards models to evaluate mortality. RESULTS: Compared to the standardized pathologic review histotype, agreement across approaches was high (kappa = 0.892 for historic, and 0.849 for IHC integrated histotype), but the IHC integrated histotype identified more low-grade serous carcinomas and a subset of endometrioid carcinomas that were assigned as high-grade serous (n = 25). No substantial differences in histotype-specific mortality were observed across approaches. CONCLUSIONS: Our findings suggest that histotype assignment is fairly consistent regardless of classification approach, but that progressive improvements in classification accuracy for some less common histotypes are achieved with pathologic review using the 2014 WHO criteria and with IHC integration. We additionally recommend a classification scheme to fit historic data into the 2014 WHO categories to answer histotype-specific research questions.
OBJECTIVE: Major changes in the classification of ovarian carcinoma histotypes occurred over the last two decades, resulting in the current 2014 World Health Organization (WHO) diagnostic criteria that recognize five principal histotypes: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. We assessed the impact of these guidelines and use of immunohistochemical (IHC) markers on classification of ovarian carcinomas in existing population-based studies. METHODS: We evaluated histotype classification for 2361 ovarian carcinomas diagnosed between 1999 and 2009 from two case-control studies using three approaches: 1. pre-2014 WHO ("historic") histotype; 2. Standardized review of pathology slides using the 2014 WHO criteria alone; and 3. An integrated IHC assessment along with the 2014 WHO criteria. We used Kappa statistics to assess agreement between approaches, and Kaplan-Meier survival curves and Cox proportional hazards models to evaluate mortality. RESULTS: Compared to the standardized pathologic review histotype, agreement across approaches was high (kappa = 0.892 for historic, and 0.849 for IHC integrated histotype), but the IHC integrated histotype identified more low-grade serous carcinomas and a subset of endometrioid carcinomas that were assigned as high-grade serous (n = 25). No substantial differences in histotype-specific mortality were observed across approaches. CONCLUSIONS: Our findings suggest that histotype assignment is fairly consistent regardless of classification approach, but that progressive improvements in classification accuracy for some less common histotypes are achieved with pathologic review using the 2014 WHO criteria and with IHC integration. We additionally recommend a classification scheme to fit historic data into the 2014 WHO categories to answer histotype-specific research questions.
Authors: Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07-23 Impact factor: 4.254
Authors: Helen J Mackay; Mark F Brady; Amit M Oza; Alexander Reuss; Eric Pujade-Lauraine; Ann M Swart; Nadeem Siddiqui; Nicoletta Colombo; Michael A Bookman; Jacobus Pfisterer; Andreas du Bois Journal: Int J Gynecol Cancer Date: 2010-08 Impact factor: 3.437
Authors: Steve E Kalloger; Martin Köbel; Samuel Leung; Erika Mehl; Dongxia Gao; Krista M Marcon; Christine Chow; Blaise A Clarke; David G Huntsman; C Blake Gilks Journal: Mod Pathol Date: 2010-12-03 Impact factor: 7.842
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: John K Chan; Deanna Teoh; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482
Authors: Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-12 Impact factor: 4.254
Authors: Martin Köbel; Anna M Piskorz; Sandra Lee; Shuhong Lui; Cecile LePage; Francesco Marass; Nitzan Rosenfeld; Anne-Marie Mes Masson; James D Brenton Journal: J Pathol Clin Res Date: 2016-07-13
Authors: Chun-Pin Chang; Yuji Chen; Brenna Blackburn; Sarah Abdelaziz; Kerry Rowe; John Snyder; Mark Dodson; Vikrant Deshmukh; Michael Newman; Joseph B Stanford; Christina A Porucznik; Jennifer Ose; Alison Fraser; Ken Smith; Jennifer Doherty; David Gaffney; Mia Hashibe Journal: Gynecol Oncol Date: 2020-02-29 Impact factor: 5.482
Authors: Aline Talhouk; Joshy George; Chen Wang; Ellen L Goode; Susan J Ramus; Jennifer A Doherty; David D Bowtell; Michael S Anglesio; Timothy Budden; Tuan Zea Tan; Derek S Chiu; Stefan Kommoss; Huei San Leong; Stephanie Chen; Maria P Intermaggio; Blake Gilks; Tayyebeh M Nazeran; Mila Volchek; Wafaa Elatre; Rex C Bentley; Janine Senz; Amy Lum; Veronica Chow; Hanwei Sudderuddin; Robertson Mackenzie; Samuel C Y Leong; Geyi Liu; Dustin Johnson; Billy Chen; Aocs Group; Jennifer Alsop; Susana N Banerjee; Sabine Behrens; Clara Bodelon; Alison H Brand; Louise Brinton; Michael E Carney; Yoke-Eng Chiew; Kara L Cushing-Haugen; Cezary Cybulski; Darren Ennis; Sian Fereday; Renée T Fortner; Jesús García-Donas; Aleksandra Gentry-Maharaj; Rosalind Glasspool; Teodora Goranova; Casey S Greene; Paul Haluska; Holly R Harris; Joy Hendley; Brenda Y Hernandez; Esther Herpel; Mercedes Jimenez-Linan; Chloe Karpinskyj; Scott H Kaufmann; Gary L Keeney; Catherine J Kennedy; Martin Köbel; Jennifer M Koziak; Melissa C Larson; Jenny Lester; Liz-Anne Lewsley; Jolanta Lissowska; Jan Lubiński; Hugh Luk; Geoff Macintyre; Sven Mahner; Iain A McNeish; Janusz Menkiszak; Nikilyn Nevins; Ana Osorio; Oleg Oszurek; José Palacios; Samantha Hinsley; Celeste L Pearce; Malcolm C Pike; Anna M Piskorz; Isabelle Ray-Coquard; Valerie Rhenius; Cristina Rodriguez-Antona; Raghwa Sharma; Mark E Sherman; Dilrini De Silva; Naveena Singh; Peter Sinn; Dennis Slamon; Honglin Song; Helen Steed; Euan A Stronach; Pamela J Thompson; Aleksandra Tołoczko; Britton Trabert; Nadia Traficante; Chiu-Chen Tseng; Martin Widschwendter; Lynne R Wilkens; Stacey J Winham; Boris Winterhoff; Alicia Beeghly-Fadiel; Javier Benitez; Andrew Berchuck; James D Brenton; Robert Brown; Jenny Chang-Claude; Georgia Chenevix-Trench; Anna deFazio; Peter A Fasching; María J García; Simon A Gayther; Marc T Goodman; Jacek Gronwald; Michelle J Henderson; Beth Y Karlan; Linda E Kelemen; Usha Menon; Sandra Orsulic; Paul D P Pharoah; Nicolas Wentzensen; Anna H Wu; Joellen M Schildkraut; Mary Anne Rossing; Gottfried E Konecny; David G Huntsman; Ruby Yun-Ju Huang Journal: Clin Cancer Res Date: 2020-06-17 Impact factor: 13.801
Authors: Bipradeb Singha; Sandra L Harper; Aaron R Goldman; Benjamin G Bitler; Katherine M Aird; Mark E Borowsky; Mark G Cadungog; Qin Liu; Rugang Zhang; Stephanie Jean; Ronny Drapkin; David W Speicher Journal: Sci Rep Date: 2018-10-03 Impact factor: 4.379
Authors: Sarah L Hulin-Curtis; James A Davies; Davor Nestić; Emily A Bates; Alexander T Baker; Tabitha G Cunliffe; Dragomira Majhen; John D Chester; Alan L Parker Journal: Cancer Gene Ther Date: 2020-01-06 Impact factor: 5.987